Stock To Watch, page-2

MEB strategies seem shrewd.

First MEB ties with Black Dog Institute, then John Hopkins University and now NAMSA, world's leading CRO, or so it claims.

Checking the NAMSA website I note that Medibio is the only client company acknowledged in the group's 2014 log of news announcements.

NAMSA has begun work on protocol development and initiated pre-submission consultations with the FDA.

It has posted this statement on website: "Pending approval by the FDA and regulators in other jurisdictions MEB plans to launch its diagnostic for depression as quickly as possible."

With yesterday's 33.3% in share price - albeit on nominal turnover - it seems the market may be finally saluting MEB's improving credentials.